Cited by 383HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual RiskHIV/AIDS drug development and treatment

PrEP stigma: implicit and explicit drivers of disparity

Open access
Golub, Sarit A.·2018·Current HIV/AIDS Reports

Abstract

Purpose of review Despite its promise as an HIV prevention strategy, PrEP uptake remains slow, especially among highest priority populations. One factor that may be impeding implementation and driving disparities is PrEP-related stigma. This paper reviews the role of PrEP-related stigma in PrEP access, adherence, and persistence and examines its antecedents and consequences. Recent findings Although PrEP stigma is often experienced at the community level (i.e., by potential and current users), it can be reinforced and even amplified by public health programs, policy, and research. PrEP stigma disproportionately impacts disadvantaged groups and impedes scalability by influencing behavior of both patients and providers. Reducing PrEP stigma and its negative impact on the epidemic requires a significant shift in perspective, language, and programs. Such a shift is necessary to ensure broader reach of PrEP as a prevention strategy and improve its utilization by the individuals who need it most.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11904-018-0385-0

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HIV/AIDS accounted for 40% of included studies.

    “In terms of health domains, HIV/AIDS accounted for 40% of included studies, consistent with prior reviews (112).”

    From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [112]

    The Introduction discusses HIV prevention and PrEP disparities, and the paper reviews PrEP-related stigma. Neither those passages nor searches for “40% of included studies” and “health domains” found a comparison of health domains or a percentage of studies concerning HIV/AIDS. (LLM, conf=0.75)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [45]Tripathi A Ogbuanu C Monger M Gibson JJ Duffus WA Pre-exposure prophylaxis for HIV infection: healthcare providers’ knowledge, perception, and willingness to adopt future implementation in the southern US Southern Medical Journal 2012 105 4 199 206 22475669

Cited by

Sorted by citations

Authors
Golub, S. A.
Affiliations
The Graduate Center, CUNY (US)
Corresponding author
Golub, Sarit A.
Venue
Current HIV/AIDS Reports
Published
2018-02-19
Volume
15
Issue
2
Pages
190-197
ISSN
  • 1548-3568 (ISSN-L)
  • 1548-3576
OpenAlex
W2792635178
Cited by
383
References
67
Citations by year
2026: 47 · 2025: 56 · 2024: 52 · 2023: 50 · 2022: 51 · 2021: 63 · 2020: 39 · 2019: 21 · 2018: 4
FWCI
4.65
Type
journal article
Language
en
Open access
Locations
  • Current HIV/AIDS Reports (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
Gilead Sciences
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
HIV PrEP, PrEP stigma, HIV prevention, PrEP uptake, health disparities, PrEP adherence, PrEP persistence, HIV prevention programs, HIV prevention policy, HIV prevention research, provider behavior, community stigma
MeSH terms
Humans, Male, HIV Infections, Anti-HIV Agents, Social Stigma, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review